ImmuCell Corporation, an animal health company, has released a corporate presentation highlighting its strategic opportunities and financial review. The presentation details the company's focus on expanding the sales of its First Defense® product line, aimed at improving herd productivity for dairy and beef calves by delivering immediate immunity. Additionally, it discusses the development of Re-Tain®, a purified Nisin product intended to address subclinical mastitis in dairy cows, reducing the reliance on traditional antibiotics. ImmuCell has made significant investments to enhance its production capacity for First Defense®, with an annual sales value target of over $30 million. The presentation also provides an update on the company's ongoing efforts to achieve FDA approval for its new manufacturing processes. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.